152 related articles for article (PubMed ID: 27798769)
21. Ipragliflozin and sitagliptin differentially affect lipid and apolipoprotein profiles in type 2 diabetes: the SUCRE study.
Nagao M; Sasaki J; Tanimura-Inagaki K; Sakuma I; Sugihara H; Oikawa S;
Cardiovasc Diabetol; 2024 Feb; 23(1):56. PubMed ID: 38331780
[TBL] [Abstract][Full Text] [Related]
22. Sitagliptin as an Initial Therapy and Differential Regulations of Metabolic Parameters Depending on its Glycemic Response in Subjects with Type 2 Diabetes.
Kutoh E; Kuto AN; Wada A; Hayashi J; Kurihara R
Drug Res (Stuttg); 2021 Mar; 71(3):157-165. PubMed ID: 33241550
[TBL] [Abstract][Full Text] [Related]
23. Alogliptin: a DPP-4 inhibitor modulating adipose tissue insulin resistance and atherogenic lipid.
Kutoh E; Kuto AN; Akiyama M; Ozawa E; Kurihara R
Eur J Clin Pharmacol; 2023 Jul; 79(7):947-959. PubMed ID: 37193913
[TBL] [Abstract][Full Text] [Related]
24. Differential effects of pioglitazone on metabolic parameters in newly diagnosed, drug-naïve Japanese patients with type 2 diabetes with or without metabolic syndrome.
Kutoh E
Endocr Res; 2010; 35(3):118-27. PubMed ID: 20712426
[TBL] [Abstract][Full Text] [Related]
25. Ipragliflozin Improves Hepatic Steatosis in Obese Mice and Liver Dysfunction in Type 2 Diabetic Patients Irrespective of Body Weight Reduction.
Komiya C; Tsuchiya K; Shiba K; Miyachi Y; Furuke S; Shimazu N; Yamaguchi S; Kanno K; Ogawa Y
PLoS One; 2016; 11(3):e0151511. PubMed ID: 26977813
[TBL] [Abstract][Full Text] [Related]
26. Safety and Effectiveness of Ipragliflozin for Type 2 Diabetes in Japan: 12-Month Interim Results of the STELLA-LONG TERM Post-Marketing Surveillance Study.
Nakamura I; Maegawa H; Tobe K; Uno S
Adv Ther; 2019 Apr; 36(4):923-949. PubMed ID: 30767112
[TBL] [Abstract][Full Text] [Related]
27. Comparison of the Pharmacokinetic and Pharmacodynamic Relationship of Ipragliflozin Between Patients With Type 1 and Type 2 Diabetes Mellitus.
Toyoshima J; Saito M; Kaibara A; Isaka H; Sakatani T
Clin Ther; 2020 Sep; 42(9):1787-1798.e3. PubMed ID: 32839028
[TBL] [Abstract][Full Text] [Related]
28. Effects of the SGLT2 inhibitor ipragliflozin on food intake, appetite-regulating hormones, and arteriovenous differences in postprandial glucose levels in type 2 diabetic rats.
Tahara A; Kondo Y; Takasu T; Tomiyama H
Biomed Pharmacother; 2018 Sep; 105():1033-1041. PubMed ID: 30021338
[TBL] [Abstract][Full Text] [Related]
29. The Sodium Glucose Cotransporter 2 Inhibitor Ipragliflozin Promotes Preferential Loss of Fat Mass in Non-obese Diabetic Goto-Kakizaki Rats.
Takasu T; Hayashizaki Y; Hirosumi J; Minoura H; Amino N; Kurosaki E; Takakura S
Biol Pharm Bull; 2017; 40(5):675-680. PubMed ID: 28458353
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetic and pharmacodynamic modelling for renal function dependent urinary glucose excretion effect of ipragliflozin, a selective sodium-glucose cotransporter 2 inhibitor, both in healthy subjects and patients with type 2 diabetes mellitus.
Saito M; Kaibara A; Kadokura T; Toyoshima J; Yoshida S; Kazuta K; Ueyama E
Br J Clin Pharmacol; 2019 Aug; 85(8):1808-1819. PubMed ID: 31026084
[TBL] [Abstract][Full Text] [Related]
31. Ipragliflozin, a sodium-glucose cotransporter 2 inhibitor, reduces bodyweight and fat mass, but not muscle mass, in Japanese type 2 diabetes patients treated with insulin: A randomized clinical trial.
Inoue H; Morino K; Ugi S; Tanaka-Mizuno S; Fuse K; Miyazawa I; Kondo K; Sato D; Ohashi N; Ida S; Sekine O; Yoshimura M; Murata K; Miura K; Arima H; Maegawa H;
J Diabetes Investig; 2019 Jul; 10(4):1012-1021. PubMed ID: 30536746
[TBL] [Abstract][Full Text] [Related]
32. [Effects of total glucosides of paeony on enhancing insulin sensitivity and antagonizing nonalcoholic fatty liver in rats].
Zheng LY; Pan JQ; Lv JH
Zhongguo Zhong Yao Za Zhi; 2008 Oct; 33(20):2385-90. PubMed ID: 19157135
[TBL] [Abstract][Full Text] [Related]
33. Tolerability and Efficacy of Ipragliflozin in The Management of Inadequately Controlled Type 2 Diabetes mellitus: A Systematic Review and Meta-analysis.
Elgebaly A; Abdelazeim N; Abdelazeim B; El Ashal G; Mattar O; Namous L; Nasreldin N
Exp Clin Endocrinol Diabetes; 2021 Jan; 129(1):56-72. PubMed ID: 29913526
[TBL] [Abstract][Full Text] [Related]
34. Clinical pharmacology study of ipragliflozin in Japanese patients with type 1 diabetes mellitus: A phase 2, randomized, placebo-controlled trial.
Kaku K; Isaka H; Toyoshima J; Sakatani T
Diabetes Obes Metab; 2019 Jun; 21(6):1445-1454. PubMed ID: 30821047
[TBL] [Abstract][Full Text] [Related]
35. Should sulfonylurea be discontinued or maintained at the lowest dose when starting ipragliflozin? A multicenter observational study in Japanese patients with type 2 diabetes.
Takahashi K; Cho KY; Nakamura A; Miya A; Miyoshi A; Yamamoto C; Nomoto H; Niwa H; Takahashi K; Manda N; Kurihara Y; Aoki S; Ito YM; Atsumi T; Miyoshi H
J Diabetes Investig; 2019 Mar; 10(2):429-438. PubMed ID: 30136403
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetic and pharmacodynamic study of ipragliflozin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study.
Kadokura T; Akiyama N; Kashiwagi A; Utsuno A; Kazuta K; Yoshida S; Nagase I; Smulders R; Kageyama S
Diabetes Res Clin Pract; 2014 Oct; 106(1):50-6. PubMed ID: 25149596
[TBL] [Abstract][Full Text] [Related]
37. Characterization of Metabolic Parameters in Responders and Nonresponders Treated with Canagliflozin Monotherapy in Drug-naive Subjects with Type 2 Diabetes.
Kutoh E; Wada A; Murayama T; Hayashi J
Indian J Endocrinol Metab; 2018; 22(2):185-190. PubMed ID: 29911028
[TBL] [Abstract][Full Text] [Related]
38. [Pharmacological and clinical profile of ipragliflozin (Suglat®): a new therapeutic agent for type 2 diabetes].
Takasu T; Takakura S; Kaku S
Nihon Yakurigaku Zasshi; 2015 Jan; 145(1):36-42. PubMed ID: 25743234
[No Abstract] [Full Text] [Related]
39. Pancreatic β-cell function relates positively to HDL functionality in well-controlled type 2 diabetes mellitus.
Dullaart RP; Annema W; de Boer JF; Tietge UJ
Atherosclerosis; 2012 Jun; 222(2):567-73. PubMed ID: 22541874
[TBL] [Abstract][Full Text] [Related]
40. A Lower Baseline Urinary Glucose Excretion Predicts a Better Response to the Sodium Glucose Cotransporter 2 Inhibitor.
Hwang YC; Kim JH; Lee BW; Lee WJ
Diabetes Metab J; 2019 Dec; 43(6):898-905. PubMed ID: 31237132
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
